Osaka, Japan

Sae Matsumoto

USPTO Granted Patents = 5 


 

Average Co-Inventor Count = 4.7

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Sae Matsumoto: Innovator in Pharmaceutical Research

Introduction

Sae Matsumoto is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target amyloid beta protein. With a total of five patents to his name, Matsumoto's work is recognized for its potential impact on treating diseases related to amyloid beta production and deposition.

Latest Patents

Matsumoto's latest patents include a sulfur-containing heterocyclic derivative that exhibits beta secretase inhibitory activity. This compound is designed as an agent for treating diseases induced by the production, secretion, and deposition of amyloid beta protein. His innovative approach aims to provide new therapeutic options for conditions associated with amyloid beta.

Career Highlights

Throughout his career, Matsumoto has been associated with Shionogi & Company Limited, a leading pharmaceutical company. His work has focused on developing novel therapeutic agents that address critical health challenges. His expertise in medicinal chemistry has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Matsumoto has collaborated with notable colleagues, including Yuuji Kooriyama and Chiaki Fujikoshi. These partnerships have fostered a collaborative environment that enhances the research and development of innovative pharmaceutical solutions.

Conclusion

Sae Matsumoto's contributions to pharmaceutical research and his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in treatments for diseases related to amyloid beta protein.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…